Premium
Erythrocytapheresis with Recombinant Human Erythropoietin in Hereditary Hemochromatosis Therapy: A New Alternative
Author(s) -
Kohan Abraham,
Niborski Ricardo,
Daruich Jorge,
Rey Jorge,
Bastos Fabiana,
Amerise Graciela,
Herrera Roberto,
García Marcelo,
Olivera Walter,
Santarelli María Teresa,
Avalos Julio Sánchez,
Findor Jorge
Publication year - 2000
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1046/j.1423-0410.2000.7910040.x
Subject(s) - phlebotomy , medicine , erythropoietin , hemochromatosis , hereditary hemochromatosis , transferrin , asymptomatic , ferritin , bloodletting , serum iron , recombinant dna , gastroenterology , anemia , endocrinology , biochemistry , pathology , biology , alternative medicine , gene
Background and Objectives: The purposes of this study were to evaluate the tolerance, efficacy and safety of isovolemic erythrocytapheresis (EA) in nonanemic patients with hereditery hemochromatosis (HH), and to assess the usefulness of recombinant human erythropoitein (rHuEPO) associated with EA to reduce treatment duration. Materials and Methods: In 10 asymptomatic patients with serum ferritin >400 μ/l, transferrin satuaration >50%, and GPT elevation, EA with rHuEPO and folic acid was performed. Results: Red Cell indices, serum ferritin, and other iron metabolism parameters (serum iron, transferrin, and transferrin satuaration)l; GPT and other laboratory data were considerably improved. Conclusion: This method offers better results in less time than traditional phlebotomy. EA with rHuEPO is an effective therapeutic alternative for patients with HH.